PNC Financial Services Group Inc. Decreases Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

PNC Financial Services Group Inc. lowered its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.4% during the third quarter, HoldingsChannel reports. The fund owned 59,255 shares of the company’s stock after selling 2,750 shares during the period. PNC Financial Services Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,068,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TEVA. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth $455,000. Caprock Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 9.9% in the 3rd quarter. Caprock Group LLC now owns 145,370 shares of the company’s stock valued at $2,620,000 after purchasing an additional 13,068 shares during the last quarter. Pathstone Holdings LLC boosted its position in shares of Teva Pharmaceutical Industries by 6.5% in the 3rd quarter. Pathstone Holdings LLC now owns 72,598 shares of the company’s stock valued at $1,308,000 after purchasing an additional 4,452 shares during the period. Swiss National Bank increased its position in Teva Pharmaceutical Industries by 0.5% during the third quarter. Swiss National Bank now owns 3,342,900 shares of the company’s stock worth $60,239,000 after buying an additional 15,300 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of NYSE:TEVA opened at $16.57 on Thursday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The firm’s 50-day simple moving average is $17.60 and its 200-day simple moving average is $17.35. The company has a market cap of $18.77 billion, a price-to-earnings ratio of -19.49, a PEG ratio of 1.30 and a beta of 0.87.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.55% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.